about
Elimination and eradication of neglected tropical diseases with mass drug administrations: a survey of expertsAntibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster-randomized clinical trialThe fitness cost of antibiotic resistance in Streptococcus pneumoniae: insight from the fieldCommunity risk factors for ocular Chlamydia infection in Niger: pre-treatment results from a cluster-randomized trachoma trialThe easiest children to reach are most likely to be infected with ocular Chlamydia trachomatis in trachoma endemic areas of NigerControl of Trachoma from Achham District, Nepal: A Cross-Sectional Study from the Nepal National Trachoma ProgramA rationale for continuing mass antibiotic distributions for trachomaReduction and return of infectious trachoma in severely affected communities in Ethiopia.Importance of coverage and endemicity on the return of infectious trachoma after a single mass antibiotic distributionImpact of mass azithromycin distribution on malaria parasitemia during the low-transmission season in Niger: a cluster-randomized trial.Nasopharyngeal Pneumococcal Serotypes Before and After Mass Azithromycin Distributions for Trachoma.Clinical activity and polymerase chain reaction evidence of chlamydial infection after repeated mass antibiotic treatments for trachomaImportance of including borderline cases in trachoma grader certificationReliability of measurements performed by community-drawn anthropometrists from rural Ethiopia.Does mass azithromycin distribution impact child growth and nutrition in Niger? A cluster-randomized trial.Childhood mortality in a cohort treated with mass azithromycin for trachoma.Efficacy of latrine promotion on emergence of infection with ocular Chlamydia trachomatis after mass antibiotic treatment: a cluster-randomized trial.Adverse events after mass azithromycin treatments for trachoma in EthiopiaReliability of trachoma clinical grading--assessing grading of marginal cases.Latrine promotion for trachoma: assessment of mortality from a cluster-randomized trial in Ethiopia.How reliable are tests for trachoma?--a latent class approach.Evidence for clonal expansion after antibiotic selection pressure: pneumococcal multilocus sequence types before and after mass azithromycin treatments.Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma.Comparison of an rRNA-based and DNA-based nucleic acid amplification test for the detection of Chlamydia trachomatis in trachoma.Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributionsTrachoma decline and widespread use of antimicrobial drugs.Association of conjunctival bacterial infection and female sex in cicatricial trachoma.Inter-grader Agreement of the Ocular Staining Score in the Sjögren's International Clinical Collaborative Alliance (SICCA) Registry.The Effect of Mass Azithromycin Distribution on Childhood Mortality: Beliefs and Estimates of Efficacy.A cluster-randomized controlled trial evaluating the effects of mass azithromycin treatment on growth and nutrition in NigerInter-Rater Agreement between Trachoma Graders: Comparison of Grades Given in Field Conditions versus Grades from Photographic ReviewThe real challenge: can we discover why trachoma is disappearing before it's gone?Adult mortality in a randomized trial of mass azithromycin for trachomaSlow resolution of clinically active trachoma following successful mass antibiotic treatments.The association between latrine use and trachoma: a secondary cohort analysis from a randomized clinical trialTopical fluoroquinolone use as a risk factor for in vitro fluoroquinolone resistance in ocular culturesA Cluster-Randomized Trial to Assess the Efficacy of Targeting Trachoma Treatment to Children.Comparison of annual versus twice-yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster-randomised trial.Travel and implications for the elimination of trachoma in ethiopia.Complete local elimination of infectious trachoma from severely affected communities after six biannual mass azithromycin distributions.
P50
Q21562239-351AB9CA-9269-4B52-A1E4-2A4244599285Q28476520-CEBE1898-BB37-4C9C-9376-4BE9D552B062Q28478903-2D3D3A7E-6198-4D8C-BA25-321BD012D181Q28482497-06F236F2-AA07-49BE-A1FB-470FA6B2857FQ28484940-1706271D-C8A4-488B-8E84-632243E1CC6DQ28550184-404F7F9C-2AC1-4ADA-94F5-F37F8A741E38Q33293477-147F1361-9BE4-4AD1-A38C-53C5DA00DABAQ33405255-EB8512AC-0E24-4D1B-99AB-9079A990DAFAQ33496749-A538C33A-CA4F-402F-9AE0-98D0AA650FB2Q33588501-84EC25AE-1220-418B-A978-6EBA0B00455EQ33609239-6A67C98A-120F-4116-BFB2-D87FBBFF59BDQ33693683-E42E4A67-6863-4A98-987A-EA2DD6BC3F14Q34138525-1E31A857-544F-44C9-9D01-46B4C1C34378Q34146015-0F618FAF-F688-4655-AAEC-3DDDCF5C1946Q34165923-B8EDFBE0-DB8D-400A-99FE-DE3AF7C10764Q35019794-5542D4EA-C566-40EB-8002-92BE67661858Q35116687-BDB47D9E-FE21-4587-91BF-14518D215827Q35131411-9BBB07E4-6A90-4F89-B1C9-4ED4282618E9Q35160381-A048B1C6-0110-46E6-95C9-DA4E37E7F3AFQ35186850-99D7C9CB-9339-4B6C-8924-92DCA4C46677Q35221151-A9E4751F-36A9-40B1-9CC6-3DF4354A86F6Q35558838-18348B19-71E9-4770-AD1A-E40A7484259CQ35632891-34F9C1D8-F023-4D5C-98E5-89EF692CB1E7Q35763113-8D11B7D7-8F31-49EB-9F83-EC750A09B3E9Q35797198-77641C9B-F157-40A8-B125-2B995DBC1D33Q35895991-4BB549BF-972C-4270-81B2-695034999D03Q36206762-1180B757-655B-4CDF-A324-F44ECA0156E5Q36296800-2692D829-4B9D-4E82-9458-DA9714B56483Q36436259-8259F1F3-8CC9-4258-8C45-74DCF033758FQ36522988-68CE362B-F1C1-488B-9246-E1D7D4BAC601Q36715056-885873C2-1BB6-48C4-98A6-3541B68031CBQ36898261-B36FC71C-7743-43EB-AFF8-5F1F3410E42FQ37109315-D47B3F4B-25C8-496B-8258-C61A10A77A89Q37174877-AF71E865-5513-4F38-B4F9-E7139DF622ABQ37225794-0482B167-35FE-4402-BE65-C9B0DAB4D206Q37315289-CD3925DD-3743-4346-A979-B22B14A5EEA4Q37835247-603E7338-2D96-4430-8B94-797EDAB0CEF9Q37849621-58B2E74C-4DD4-43A3-B295-984C83A36897Q37853415-391491C5-1BC0-474C-8F13-69A4CD987ADBQ37854318-638566EC-C52A-4F91-8393-9BD98E521383
P50
name
Bruce Gaynor
@en
type
label
Bruce Gaynor
@en
prefLabel
Bruce Gaynor
@en